# FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

> **NCT01359007** · PHASE2 · TERMINATED · sponsor: **University of Oklahoma** · enrollment: 5 (actual)

## Conditions studied

- Adenocarcinoma of Pancreas

## Interventions

- **DRUG:** Irinotecan, Oxaliplatin, Leucovorin, 5-FU

## Key facts

- **NCT ID:** NCT01359007
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The principal investigator terminated the study due to inactivity and low enrollment
- **Last updated:** 2018-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01359007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01359007, "FOLFIRINOX in Patients With Inoperable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01359007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*